https://orcid.org/0000-0001-5112-3893
References
- Al-Mulla NA, Taj-Aldeen SJ, El Shafie S, et al. Bacterial bloodstream infections and antimicrobial susceptibility pattern in pediatric hematology/oncology patients after anticancer chemotherapy. Infect Drug Resist. 2014;7:289–299. PMID: 25395866; PMCID: PMC4226521. doi:10.2147/IDR.S70486
- Montassier E, Batard E, Gastinne T, et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–850. doi:10.1007/s10096-013-1819-7
- Asturias EJ, Corral JE, Quezada J. Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia. Curr Oncol. 2010;17(2):59–63. doi:10.3747/co.v17i2.453
- Vento D. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention and treatment. Lancet Oncol. 2003;4(10):595–604. doi:10.1016/S1470-2045(03)01218-X
- Duncan C, Chisholm JC, Freeman S, et al. A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England. Pediatr Blood Cancer. 2007;49(5):678–681. doi:10.1002/pbc.21041
- Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a Phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006;24(4):563–570. PMID: 16446328. doi:10.1200/JCO.2005.03.2847
- Lehrnbecher T, Fisher BT, Phillips B, et al. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis. 2020;71(1):226–236. PMID: 31676904; PMCID: PMC7312235. doi:10.1093/cid/ciz1082
- Choi SW, Chang L, Hanauer DA, et al. Rapid reduction of central line infections in hospitalized pediatric oncology patients through simple quality improvement methods. Pediatr Blood Cancer. 2013;60(2):262–269; PMID: 22522576; PMCID: PMC3720122. doi: 10.1002/pbc.24187
- Villafuerte-Gutierrez P, Villalon L, Losa JE, et al. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;2014:986938. doi:10.1155/2014/986938
- Humphries RM, Kircher S, Ferrell A, et al. The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: report from the clinical and laboratory standards institute methods development and standardization working group. J Clin Microbiol. 2018;56(8):e00437–18. PMID: 29743302; PMCID: PMC6062797. doi:10.1128/JCM.00437-18
- Ammann RA, Laws HJ, Schrey D, et al. Bloodstream infection in paediatric cancer centres–leukaemia and relapsed malignancies are independent risk factors. Eur J Pediatr. 2015;174(5):675–686. PMID: 25804192. doi:10.1007/s00431-015-2525-5
- Tural Kara T, Erat T, Yahşi A, et al. Bloodstream infections in pediatric hematology/oncology patients: six years’ experience of a single center in Turkey. Turk J Med Sci. 2019;49(4):1157–1164. PMID: 31342734; PMCID: PMC7018311. doi:10.3906/sag-1812-101
- Hassan B, Yusoff Z, Othman S. Association of neutropenia onset and severity with chemotherapy regimens and schedules. Asian Pac J Cancer Prev. 2011;12(6):1425.
- Hua LV, Hing BH, Ning B. Pathogenesis of bloodstream infection in children with blood cancer. Exp Ther Med. 2013;5(1):201–204. doi:10.3892/etm.2012.738
- Kuo FC, Wang SM, Shen CF, et al. Bloodstream infections in pediatric patients with acute leukemia: emphasis on gram-negative bacteria infections. J Microbiol Immunol Infect. 2017;50(4):507–513. doi:10.1016/j.jmii.2015.08.013
- Zengin E, Sarper N, Kılıç SC. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatr Hematol Oncol. 2011;28(4):311–320. PMID: 21524156. doi:10.3109/08880018.2011.557144